MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-17-2026
NeoGenomics Total Liabilities 2011-2026 | NEO
Annual Total Liabilities NeoGenomics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 523 M | 736 M | 740 M | 742 M | 762 M | 294 M | 202 M | 185 M | 138 M | 151 M | 130 M | 20.7 M | 18.2 M | 20.9 M | 14.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 762 M | 14.1 M | 312 M |
Quarterly Total Liabilities NeoGenomics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 540 M | 713 M | 736 M | 733 M | 727 M | 717 M | 740 M | 731 M | 739 M | 735 M | 742 M | 743 M | 749 M | 755 M | 762 M | 769 M | 748 M | 651 M | 294 M | 294 M | 294 M | 294 M | 202 M | 202 M | 202 M | 202 M | 185 M | 185 M | 185 M | 185 M | 140 M | 140 M | 140 M | 140 M | 151 M | 151 M | 151 M | 151 M | 113 M | 113 M | 113 M | 113 M | 20.7 M | 20.7 M | 20.7 M | 20.7 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 14.1 M | 14.1 M | 14.1 M | 14.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 769 M | 14.1 M | 304 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Burning Rock Biotech Limited
BNR
|
433 M | $ 15.85 | -2.49 % | $ 171 M |  China |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Agilent Technologies
A
|
5.32 B | $ 115.06 | -0.29 % | $ 35 B | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
29.2 M | $ 1.13 | -2.59 % | $ 6.15 M | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 16.05 | -3.83 % | $ 855 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 2.3 | - | $ 10.2 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 23.13 | -1.28 % | $ 642 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 175.65 | 0.06 % | $ 8.71 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 493.53 | -1.59 % | $ 14.2 B | USA |
 |
Danaher Corporation
DHR
|
31.8 B | $ 189.61 | -1.7 % | $ 135 B | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 120.93 | -2.22 % | $ 19.2 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.35 | -2.03 % | $ 403 M | USA |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 14.43 | -3.93 % | $ 436 M | USA |
 |
Guardant Health
GH
|
2.11 B | $ 78.6 | -9.83 % | $ 9.85 B | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
2.13 M | $ 2.69 | -1.82 % | $ 87.3 K | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.13 | -0.9 % | $ 4.89 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 28.31 | 0.62 % | $ 20 B | Niderland |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 106.81 | 0.1 % | $ 8.81 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 260.93 | -4.51 % | $ 21.7 B | USA |
 |
Natera
NTRA
|
689 M | $ 193.03 | -4.91 % | $ 19 B | USA |
 |
Celcuity
CELC
|
366 M | $ 117.14 | -6.02 % | $ 5.48 B | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 80.59 | -1.03 % | $ 5.44 B | USA |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 6.68 | 0.15 % | $ 279 M | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Soleno Therapeutics
SLNO
|
114 M | $ 52.63 | 0.23 % | $ 2.67 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 191.51 | -3.19 % | $ 21.3 B | USA |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 9.42 | -6.13 % | $ 2.04 B | USA |
 |
ENDRA Life Sciences
NDRA
|
1.59 M | $ 4.94 | -6.97 % | $ 3.89 M | USA |
 |
Neuronetics
STIM
|
115 M | $ 1.35 | -2.17 % | $ 89 M | USA |
 |
National Research Corporation
NRC
|
121 M | $ 16.48 | -3.34 % | $ 369 M | USA |